---
input_text: Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating
  agents in newly diagnosed AML patients. Hypomethylating agent (HMA) plus venetoclax
  (VEN) regimens are standard of care in patients with acute myeloid leukemia (AML)
  ineligible for intensive chemotherapy. While the VEN label recommends continuous
  28-day cycles, shortened VEN durations may induce similar response rates and improve
  tolerability. It is unknown how a VEN exposure reduced to 7 days during cycles compares
  to standard HMA + VEN. We retrospectively compared newly diagnosed AML patients
  treated with azacitidine (AZA) x 7 days plus VEN x 7 days ("7 + 7" regimen) from
  the first cycle (n = 82) vs patients treated with standard dose HMA + VEN (std-HMA/VEN)
  (n = 166). Composite complete remission rate was similar between cohorts (72% vs
  72%; p = 0.95) and a median number of cycles to best response was 2 with "7 + 7"
  vs 1 with std-HMA/VEN (p = 0.03). Concerning toxicity, platelet transfusion rates
  during cycle 1 as well as early mortality at 8-weeks (6% vs 16%; p = 0.03) were
  lower in "7 + 7" cohort. Finally, the median OS was 11.2 months (2-year 28%) with
  "7 + 7" vs 10.3 months (2-year 34%) with "std-HMA/VEN" (p = 0.75). In summary, acknowledging
  limitations of a retrospective comparison, a shortened course of VEN used for 7
  days every 28 days resulted in similar response rates and survival when compared
  to standard VEN exposure.
raw_completion_output: |-
  primary_disease: Acute myeloid leukemia (AML)

  medical_actions: Hypomethylating agent (HMA) plus venetoclax (VEN) regimens; Azacitidine (AZA) x 7 days plus VEN x 7 days treatment; Standard dose HMA + VEN treatment; Platelet transfusion

  symptoms: High mortality at 8-weeks

  chemicals: Venetoclax (VEN); Azacitidine (AZA)

  action_annotation_relationships: Hypomethylating agent (HMA) plus venetoclax (VEN) regimens TREATS Acute myeloid leukemia (AML); Azacitidine (AZA) x 7 days plus VEN x 7 days treatment TREATS Acute myeloid leukemia (AML); Standard dose HMA + VEN treatment TREATS Acute myeloid leukemia (AML); Platelet transfusion TREATS High mortality at 8-weeks IN Acute myeloid leukemia (AML)
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  Platelet transfusion TREATS High mortality at 8-weeks IN Acute myeloid leukemia (AML)

  ===

extracted_object:
  primary_disease: MONDO:0018874
  medical_actions:
    - Hypomethylating agent (HMA) plus venetoclax (VEN) regimens
    - Azacitidine (AZA) x 7 days plus VEN x 7 days treatment
    - Standard dose HMA + VEN treatment
    - MAXO:0001490
  symptoms:
    - High mortality at 8-weeks
  chemicals:
    - CHEBI:133021
    - CHEBI:2038
  action_annotation_relationships:
    - subject: regimens
      predicate: TREATS
      object: HP:0004808
      subject_extension: CHEBI:76400
    - subject: treatment
      predicate: TREATS
      object: HP:0004808
      subject_qualifier: x 7 days
      subject_extension: Azacitidine (AZA) plus Venetoclax (VEN)
    - subject: treatment
      predicate: TREATS
      object: HP:0004808
      subject_qualifier: Standard dose
      subject_extension: HMA + VEN
    - subject: MAXO:0001490
      predicate: TREATS
      object: High mortality at 8-weeks
      qualifier: MONDO:0018874
named_entities:
  - id: MONDO:0018874
    label: Acute myeloid leukemia (AML)
  - id: HP:0001945
    label: Fever
  - id: HP:0012378
    label: Fatigue
  - id: MONDO:0020512
    label: T cell acute lymphoblastic leukemia (T-ALL)
  - id: HP:0006727
    label: T-ALL
  - id: CHEBI:50131
    label: Decitabine
  - id: CHEBI:133021
    label: Venetoclax
  - id: HP:0004808
    label: Acute myeloid leukemia
  - id: HP:0002090
    label: pneumonia
  - id: HP:0100806
    label: sepsis
  - id: CHEBI:71019
    label: Homoharringtonine
  - id: CHEBI:28680
    label: Cytarabine
  - id: HP:0000739
    label: anxiety
  - id: HP:0000716
    label: depression
  - id: CHEBI:190514
    label: dasatinib
  - id: CHEBI:23456
    label: cyclodextrins
  - id: MAXO:0000747
    label: Hematopoietic Stem Cell Transplantation (HSCT)
  - id: MAXO:0000647
    label: Chemotherapy
  - id: HP:0002018
    label: Nausea
  - id: HP:0002094
    label: Dyspnea
  - id: HP:0100785
    label: Insomnia
  - id: HP:0012531
    label: Pain
  - id: HP:0002019
    label: Constipation
  - id: CHEBI:2038
    label: Azacitidine
  - id: CHEBI:197440
    label: Tumor necrosis factor-alpha (TNF-alpha)
  - id: MONDO:0004967
    label: Acute Lymphoblastic Leukemia (ALL)
  - id: CHEBI:8378
    label: Prednisolone
  - id: HP:0000001
    label: Acute Lymphoblastic Leukemia (ALL)
  - id: HP:0001297
    label: Stroke
  - id: HP:0001635
    label: Heart failure
  - id: HP:0001677
    label: Coronary atherosclerosis
  - id: MONDO:0004992
    label: Cancer
  - id: MAXO:0001479
    label: allogeneic hematopoietic stem cell transplantation (allo-HSCT)
  - id: MONDO:0004947
    label: B-cell acute lymphoblastic leukemia
  - id: MAXO:0000757
    label: infusion
  - id: MAXO:0000602
    label: Hemodialysis
  - id: HP:0003326
    label: Myalgia
  - id: HP:0002039
    label: Anorexia
  - id: HP:0100519
    label: Anuria
  - id: HP:0011037
    label: Decreased urine output
  - id: HP:0001919
    label: Acute kidney injury
  - id: CHEBI:18332
    label: Levothyroxine
  - id: MONDO:0020511
    label: Acute B-lymphoblastic leukemia (B-ALL)
  - id: HP:0003419
    label: lower back pain
  - id: MONDO:0010651
    label: high-risk myelodysplastic neoplasm (MDS)
  - id: CHEBI:30621
    label: arsenic trioxide
  - id: HP:0002360
    label: sleep disturbances
  - id: MONDO:0017361
    label: Cytokine release syndrome (CRS)
  - id: CHEBI:64360
    label: Tocilizumab
  - id: MONDO:0012883
    label: Acute promyelocytic leukemia (APL)
  - id: MAXO:0000149
    label: Allogeneic hematopoietic cell transplantation (HCT)
  - id: MONDO:0004948
    label: chronic lymphocytic leukemia
  - id: HP:0002014
    label: diarrhea
  - id: CHEBI:63791
    label: lenalidomide
  - id: HP:0005550
    label: chronic lymphocytic leukemia
  - id: MONDO:0003864
    label: Chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL)
  - id: MAXO:0001298
    label: therapies
  - id: CHEBI:42068
    label: Idarubicin
  - id: HP:0032169
    label: severe infections
  - id: CHEBI:55379
    label: cyclosporine (CsA)
  - id: CHEBI:85010
    label: eltrombopag
  - id: CHEBI:85012
    label: thrombopoietin receptor agonist (TPO-RA)
  - id: MAXO:0001394
    label: oral administration
  - id: MAXO:0001525
    label: intravenous administration
  - id: HP:0002315
    label: Headache
  - id: CHEBI:50858
    label: Corticosteroids
  - id: HP:0100614
    label: myositis
  - id: CHEBI:26708
    label: NA
  - id: CHEBI:76612
    label: Ibrutinib
  - id: CHEBI:167707
    label: Acalabrutinib
  - id: CHEBI:145428
    label: glasdegib
  - id: MONDO:0100096
    label: COVID-19
  - id: MAXO:0010030
    label: bone marrow transplantation
  - id: HP:0001903
    label: anemia
  - id: HP:0001875
    label: neutropenia
  - id: HP:0001698
    label: pericardial effusion
  - id: CHEBI:35705
    label: immunosuppressants
  - id: MONDO:0019460
    label: Acute leukemia of ambiguous lineage (ALAL)
  - id: HP:0001873
    label: Thrombocytopenia
  - id: CHEBI:62434
    label: FLT3 inhibitor
  - id: CHEBI:38637
    label: Tyrosine kinase inhibitor
  - id: CHEBI:28748
    label: Doxorubicin (Dox)
  - id: HP:0020174
    label: drug resistance
  - id: CHEBI:23888
    label: drugs
  - id: MONDO:0018689
    label: Plasma cell leukemia
  - id: HP:0031047
    label: monoclonal gammopathy
  - id: CHEBI:52726
    label: proteasome inhibitor
  - id: CHEBI:35341
    label: steroids
  - id: CHEBI:48120
    label: anthracyclines
  - id: MONDO:0001881
    label: Septic shock
  - id: MAXO:0001021
    label: Antimicrobial treatment
  - id: MAXO:0000174
    label: Antifungal treatment
  - id: HP:0001876
    label: Pancytopenia
  - id: CHEBI:133748
    label: Citrate
  - id: CHEBI:41879
    label: Dexamethasone
  - id: HP:0001909
    label: leukemia
  - id: CHEBI:33281
    label: Antimicrobial
  - id: CHEBI:35718
    label: Antifungal
  - id: MONDO:0011996
    label: Chronic Myeloid Leukemia
  - id: CHEBI:46345
    label: 5-fluorouracil
  - id: HP:0005506
    label: chronic myeloid leukemia
  - id: MONDO:0005059
    label: Leukemia
  - id: CHEBI:41977
    label: Daunorubicin
  - id: CHEBI:50729
    label: Mitoxantrone
  - id: CHEBI:50924
    label: Sorafenib
  - id: CHEBI:145372
    label: Gilteritinib
  - id: CHEBI:90217
    label: Quizartinib
  - id: CHEBI:145410
    label: IDH inhibitors
  - id: CHEBI:233585
    label: BAM15
  - id: CHEBI:197439
    label: TNFalpha
  - id: CHEBI:45716
    label: SAHA (Vorinostat)
  - id: HP:0002202
    label: Pleural effusion
  - id: HP:0030357
    label: small cell lung cancer
  - id: HP:0012570
    label: synovial sarcoma
  - id: CHEBI:4027
    label: Cyclophosphamide
  - id: MAXO:0000753
    label: Bone marrow examination
  - id: MONDO:0600008
    label: Cytokine release syndrome
  - id: MONDO:0020311
    label: chronic myelomonocytic leukemia
  - id: HP:0012325
    label: chronic myelomonocytic leukemia
  - id: HP:0002488
    label: Acute leukemia
  - id: HP:0003201
    label: Rhabdomyolysis
  - id: HP:0033677
    label: Acute respiratory distress syndrome (ARDS)
  - id: MONDO:0000922
    label: <Primary immunodeficiency disorders (PIDs)>
  - id: MAXO:0000068
    label: transplantation
  - id: HP:0002910
    label: elevated liver function tests
  - id: CHEBI:567361
    label: cladribine
  - id: MAXO:0000016
    label: cell therapy
  - id: CHEBI:231683
    label: Anakinra
  - id: CHEBI:66919
    label: Ruxolitinib
  - id: CHEBI:46081
    label: Fluconazole
  - id: CHEBI:28001
    label: vancomycin
  - id: CHEBI:46765
    label: carbapenems
  - id: CHEBI:63607
    label: linezolid
  - id: CHEBI:149836
    label: tigecycline
  - id: CHEBI:23066
    label: cephalosporins
  - id: CHEBI:85989
    label: ceftazidime/avibactam
  - id: CHEBI:37943
    label: colistin
  - id: MONDO:0004963
    label: T-cell acute lymphoblastic leukemia
  - id: HP:0003077
    label: Hyperlipidemia
  - id: HP:0003124
    label: Elevated total cholesterol
  - id: HP:0025502
    label: overweight
  - id: HP:0004812
    label: B-cell acute lymphoblastic leukemia
  - id: MONDO:0011908
    label: Juvenile myelomonocytic leukemia (JMML)
  - id: MAXO:0010033
    label: umbilical cord blood transplantation
  - id: CHEBI:28901
    label: busulfan
  - id: HP:0012209
    label: JMML
  - id: HP:0031375
    label: refractory
  - id: MAXO:0001490
    label: Platelet transfusion
  - id: CHEBI:76400
    label: Hypomethylating agent (HMA) plus venetoclax (VEN)
